Literature DB >> 16479540

Alpha-melanocyte-stimulating hormone down-regulates CXC receptors through activation of neutrophil elastase.

Sunil K Manna1, Abira Sarkar, Yashin Sreenivasan.   

Abstract

Considering the role of interleukin-8 (IL-8) in a large number of acute and chronic inflammatory diseases, the regulation of IL-8-mediated biological responses is important. Alpha-melanocyte-stimulating hormone (alpha-MSH), a tridecapeptide, inhibits most forms of inflammation by an unknown mechanism. In the present study, we have found that alpha-MSH interacts predominantly with melanocortin-1 receptors and inhibits several IL-8-induced biological responses in macrophages and neutrophils. It down-regulated receptors for IL-8 but not for TNF, IL-4, IL-13 or TNF-related apoptosis-inducing ligand (TRAIL) in neutrophils. It down-regulated CXCR type 1 and 2 but not mRNA levels. alpha-MSH did not inhibit IL-8 binding in purified cell membrane or affinity-purified CXCR. IL-8 or anti-CXCR Ab protected against alpha-MSH-mediated inhibition of IL-8 binding. The level of neutrophil elastase, a specific serine protease, but not cathepsin G or proteinase 3 increased in alpha-MSH-treated cells, and restoration of CXCR by specific neutrophil elastase or serine protease inhibitors indicates the involvement of elastase in alpha-MSH-induced down-regulation of CXCR. These studies suggest that alpha-MSH inhibits IL-8-mediated biological responses by down-regulating CXCR through induction of serine protease and that alpha-MSH acts as a potent immunomodulator in neutrophil-driven inflammatory distress.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16479540     DOI: 10.1002/eji.200535209

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  17 in total

Review 1.  Melanocyte receptors: clinical implications and therapeutic relevance.

Authors:  J Andrew Carlson; Gerald P Linette; Andrew Aplin; Bernard Ng; Andrzej Slominski
Journal:  Dermatol Clin       Date:  2007-10       Impact factor: 3.478

2.  Short-term exposure to oleandrin enhances responses to IL-8 by increasing cell surface IL-8 receptors.

Authors:  Nune Raviprakash; Sunil Kumar Manna
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

3.  The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties.

Authors:  Trinidad Montero-Melendez; Hetal B Patel; Michael Seed; Søren Nielsen; Thomas E N Jonassen; Mauro Perretti
Journal:  Am J Pathol       Date:  2011-05-10       Impact factor: 4.307

4.  Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells.

Authors:  Yashin Sreenivasan; Pongali B Raghavendra; Sunil K Manna
Journal:  J Clin Immunol       Date:  2006-06-16       Impact factor: 8.317

Review 5.  Negative regulators that mediate ocular immune privilege.

Authors:  Andrew W Taylor; Tat Fong Ng
Journal:  J Leukoc Biol       Date:  2018-02-12       Impact factor: 4.962

6.  Advanced glycation end products (AGEs) induce apoptosis via a novel pathway: involvement of Ca2+ mediated by interleukin-8 protein.

Authors:  Sidharth Mahali; Nune Raviprakash; Pongali B Raghavendra; Sunil K Manna
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

7.  Azadirachtin interacts with the tumor necrosis factor (TNF) binding domain of its receptors and inhibits TNF-induced biological responses.

Authors:  Maikho Thoh; Pankaj Kumar; Hampathalu A Nagarajaram; Sunil K Manna
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

8.  Diminishment of alpha-MSH anti-inflammatory activity in MC1r siRNA-transfected RAW264.7 macrophages.

Authors:  Dayu Li; Andrew W Taylor
Journal:  J Leukoc Biol       Date:  2008-04-03       Impact factor: 4.962

9.  The neuropeptides α-MSH and NPY modulate phagocytosis and phagolysosome activation in RAW 264.7 cells.

Authors:  Toan A Phan; Andrew W Taylor
Journal:  J Neuroimmunol       Date:  2013-05-17       Impact factor: 3.478

10.  Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells.

Authors:  Franco Capsoni; Anna Maria Ongari; Eva Reali; Anna Catania
Journal:  Arthritis Res Ther       Date:  2009-10-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.